Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedNo additions or deletions are present for this page. The content remains unchanged.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' as a condition listing and included a new Resources section linking the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check16 days agoChange DetectedThe two screenshots show no observable changes to the page content or structure; the study details page appears identical.SummaryDifference0.1%

- Check24 days agoChange DetectedRevision metadata updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check31 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check59 days agoChange DetectedAdded a site revision note (Revision: v3.4.2) and removed the previous funding-status notice and prior revision (v3.4.1). These are administrative changes to the site rather than changes to the study content.SummaryDifference0.5%

Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.